A possibly more precise risk model showed Adempas helped PAH patients at intermediate risk of death arrive at more favorable ...
The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback